Contact UsCareersNewsScienceContact Us
News & Media

Discover our presence in global media here

HomeNewsPRESS RELEASES

2022

June 13, 2022
Pfizer launches India’s first free of cost Online Education Platform on AMR in regional languages for Nurses
May 4, 2022
Pfizer sets up global drug development center in India
April 5, 2022
INDovation program to incubate and commercialise Indian healthcare start-ups launched
March 30, 2022
Pfizer launches Project Aastha Cancer-Care Services and Helpdesk at The Gujarat Cancer & Research Institute, Ahmedabad
March 10, 2022
Pfizer launches its 6th helpdesk in cancer hospitals in India
March 7, 2022
Pfizer launches Project Aastha Cancer-Care Services and Helpdesk at the Regional Cancer Center in Raipur
February 21, 2022
Pfizer’s support to Tata Trusts Cancer Care Programme helps enroll and screen close to 70,000 people for NCDs and Cancer within a year
February 7, 2022
Mr. Pradip Shah appointed as Chairman of Pfizer Limited Board

2021

June 4, 2021
Pfizer supports deployment of 400 oxygen beds for adult and pediatric patients in Delhi and ICU beds in Mumbai COVID care facilities
May 26, 2021
Pfizer Limited revenue from operations for the quarter and year ended March 31, 2021 at ₹535 crore and ₹2,239 crore respectively

2020

November 2, 2020
Pfizer Limited revenue from operations at ₹595 crores for the quarter ended September 30, 2020
July 27, 2020
Pfizer Limited revenue from operations at ₹515 crores for the quarter ended June 30, 2020
June 15, 2020
Pfizer Limited revenue from operations at ₹502 crore for the quarter ended March 31, 2020

VIEW ALL

PFIZER IN NEWS

2022

Pfizer India inks partnership with Father Muller Research to award fellowships to younger scientists

MSN - (Sep 26)

Biopharmaceutical major Pfizer India on Monday announced that it has signed a Memorandum of Understanding (MoU) with Father Muller Research to give fellowship opportunities to young researchers for gathering real-world evidence on drug efficacy and proven therapies from existing Electronic Patient records. Read more

Pfizer India partners with Father Muller Research to strengthen evidence generation in cancer and CVDs

The Economic Times - (Sep 26)

The aim of the partnership is to enhance scope of care and create avenues for new research. Researchers will access existing electronic health record to develop a deeper understanding on drug efficacy in proven therapies. It will focus on evidence generation on prevention, treatment and management of diseases such as cancer and cardiovascular diseases. Read more

Six start-ups in Oncology and Digital Health to receive grants of 65 lacs each under Pfizer's INDovation Program 

The Economic Times - (Sep 15)

Program supported by Pfizer Limited (“Pfizer”), Atal Innovation Mission (AIM), NITI Aayog, Social Alpha, Foundation for Innovation and Technology Transfer (FITT), IIT-Delhi and AGNIi; with UN Health Innovation Exchange (UNHIEX) as knowledge partner. Customised incubation support across technology incubation centers like the IITs and other major technology institutes across India; grant upto Rs. 65 lacs per selected start-up. Read more

Hyderabad startup gets Pfizer grant 

Times Of India - (Sep 14)

City-based Oncophenomics Life Sciences has received a grant of 65 lakh under Pfizer's incubation programme. Read more

Start-ups Receive Grants Of 65 Lacs Each Under Pfizer’s INDovation Program

BW Healthcare World - (Sep 13)

The six winners who will be given a grant of Rs. 65 lacs each will receive incubation support from AIM, NITI Aayog and IIT Delhi. Pfizer will provide the grant as well as mentorship and technical assistance to the start-ups and Social Alpha will provide program acceleration support. Read more

Six health start-ups to get Rs 65 lakhs each under Pfizer's INDovation programme

Money Control - (Sep 12)

Pfizer will provide the grant as well as mentorship and technical assistance to the six winning health start-ups while its programme partner Social Alpha will provide the programme acceleration support. Read more

Disseminating bottom-up approach to AMR is a necessity

The Economic Times - (Aug 5)

A country with one of the heaviest burdens of infectious diseases and drug-resis tant pathogens, while also being a country renowned for the prowess of its pharmaceuticals industry, quality of science and innovative public and academic instiutions, there is no reason why the next global breakthrough anti-infective drug should not come from India. Read more

Pfizer India, Max Hospitals join hands to promote research on drug efficacy

Money Control - (Jul 15)

The research will focus on prevention, treatment and management of diseases that are of public health priority in India such as cancer and cardiovascular diseases. Read more

Pfizer India, Max Hospitals sign MoU for fellowship programme

The Economic Times - (Jul 15)

The aim of the partnership is to enhance scope of care and create avenues for new research. Researchers will access existing Electronic Health Record to develop a deeper understanding on drug efficacy in proven therapies. Read more

How Digitalization Is Transforming the World of Healthcare

The Economic Times - (Jul 12)

This digital transformation is not only going to revolutionize the market model, but also the mindset and approach of patients and healthcare professionals alike. Read more

From AstraZeneca to Pfizer, Big Pharma is banking on India’s data and IT chops for cutting-edge R&D

The Economic Times - (Jun 24)

When a deadly virus had the world in its grip two years ago, scientists were faced with an uphill task of finding a vaccine and fast. Read more

Hike in cash aid for patients with rare diseases raises hopes for entry of new ‘orphan drugs’ in India

Money Control - (Jun 7)

The change has come through a modification in the National Policy for Rare Diseases, which was first notified in 2021. Read more

Pfizer’s 1st drug development lab in Asia opens in Chennai

The Economic Times - (May 5)

US pharmaceutical company Pfizer has set up its global drug development centre at the Indian Institute of Technology-Madras Research Park here, at an outlay of over Rs 150 crore. Read more

Pfizer makes big R&D push in India

Mint - (May 5)

The 61,000 sq. ft centre, built at $20 million, will be part of a network of 12 Pfizer global centres. Read more

Pfizer Sets Up Asia's First Global Drug Development Centre In Chennai

NDTV - (May 4)

Pfizer has invested USD 20 million (INR 150 crore) in the 61,000 sq ft research and technology centre at the IIT Madras Research Park. Read more

Pfizer sets up global drug development centre in India

India Today - (May 4)

Pfizer has set up a centre to develop APIs and finished dosage forms of differentiated products for global markets, at the IIT Madras Research Park campus in Chennai. Read more

Pfizer Indovation Program To Back Oncology, Healthcare Startups In India | StartUp Central

Times Now - (Apr 9)

Pfizer launches the Pfizer INDovation Program to back Oncology, Healthcare Startups in India. It will grant Rs 65 lakh to each of the three winning startups. Read more

Pfizer offers voluntary retirement scheme for field staff

PTI News - (Apr 7)

Drug firm Pfizer Ltd on Thursday offered a voluntary retirement scheme (VRS) for its field staff as part of expanding its digital capabilities and revamping talent strategy. Read more

Seven organisations come together to launch INDovation programme to incubate and commercialise Indian healthcare startups

Express Pharma - (Apr 6)

The programme is supported by Pfizer, Atal Innovation Mission (AIM), NITI Aayog, Social Alpha, Foundation for Innovation and Technology Transfer (FITT), IIT-Delhi and AGNIi; with UN Health Innovation Exchange (UNHIEX) as knowledge partner. Read more

Pfizer to back startups in India working on oncology, digital health

The Economics Times - (Apr 6)

Pfizer will provide grants of up to Rs 65 lakh and two years of incubation support through the Indian Institutes of Technology (IITs) and other top academic institutions to six startups, starting with three in the first year. Read more

Pfizer launches Project Aastha helpdesk at RCC, Pandit Jawaharlal Nehru Memorial Medical College, Raipur

The Economic Times- (Mar 10)

The helpdesk, set up in the R block of the hospital, will support patients with support patients with registration; travel booking information and support; local accommodation guidance and linkages among other services. Read more

Pfizer’s support to Tata Trusts Cancer Care programme

Indian Express - (Feb 23)

Pfizer has announced that its support to Tata Trusts Cancer Care programme since 2020 has helped in enrolling and screening 70,000 people for non-communicable diseases (NCDs) and cancer across Assam, Jharkhand and Andhra Pradesh. Read more

Pfizer supports Tata Trusts Cancer Care Programme

The Pioneer - (Feb 22)

Pfizer today announced that its support to Tata Trusts Cancer Care programme since 2020 has helped in enrolling and screening 70,000 people for non-communicable diseases (NCDs) and Cancer across Assam, Jharkhand and Andhra Pradesh. Read more

Pradip Shah appointed Pfizer India chairman

Times Of India - (Feb 7)

Pfizer India on Monday appointed Pradip Shah as the chairman of its board following the resignation  of R A Shah on February 3. Read more

Pradip Shah elevated as Chairman of the Board of Pfizer Limited

The Economic Times - (Feb 7)

Shah has been on the Board of Pfizer since December 1999 and has been guiding the Board and Management on various financial and strategic decisions. Read more

2021

Antibiotics overuse: “With resistance to 1st and 2nd line antibiotics, doctors forced to use reserve drugs”

The Times of India - (Dec 8)

Sir Alexander Fleming in his Nobel lecture in 1945 said, “The time may come when penicillin can be bought by anyone in the shops. Read more

AMR: What to do, what not to do – those are the questions!

The Times of India - (Dec 3)

Imagine reading a newspaper headline that said: “2 million Indians succumbed to a particular disease or condition in just one year.” Read more

Three essential facts on lung infections

The New Indian Express - (Dec 2)

India accounts for 23 per cent of the global pneumonia burden with case fatality rates between 14 and 30 per cent. Read more

Essential things to know about lung infections on World Pneumonia Day

Financial Express - (Nov 12)

India accounts for 23% of global pneumonia burden with case fatality rates between 14% and 30%, and the bacteria Streptococcus pneumoniae is considered a major bacterial cause.Read more

FDA authorises Pfizer vaccine for teens

Business Standard - Mumbai / Delhi / Pune / Bangalore / Hyderabad / Chennai / Kolkata / Kochi / Ahmedabad / Chandigarh(May 12)

​​​​​​​US regulators expanded the use of Pfizers’ Covid-19 vaccine to children as young as 12 offering a way to protect the nations adolescents before they head back to school in the fall and paving the way for them to return to more normal activities.Read more

Sri Lanka approves Pfizer shot

The Hindu - Delhi / Mumbai / Bangalore / Hyderabad / Chennai / Kolkata / Kochi / Chandigarh(May 09)

Sri Lanka on Saturday approved Pfizers’ COVID-19 vaccine for emergency use in Sri Lanka as the island nation battles a third wave of the virus while suffering a restricted supply of vaccines from neighbouring India.Read more

Pfizer's Covid jab provides 95% protection, says study

Hindustan Times - Delhi / Mumbai / Pune / Chandigarh / Faridabad / Gurgaon / Noida(May 07)

The largest real-world study yet of the Pfizer-BioNTech vaccine on Thursday confirmed that the jab provided more than 95% protection against Covid-19 but found that the level dropped when people received just one of the two prescribed doses.Read more

Pfizer donates $70 mn supplies to india to aid covid treatment

Hindustan Times - Delhi / Mumbai / Chandigarh / Gurgaon(May 04)

Rhythma Kaul

US pharma giant Pfizer has donated medical supplies worth $70 million including drugs to treat the coronavirus disease (Covid-19) to India the company said in a statement on Monday adding that it was in talks with the Indian government to expedite its Covid-19 vaccine approval. Read more

Pfizer in talks with govt over 'expedited nod' for vaccine

The Indian Express - Delhi / Mumbai / Pune / Kolkata / Ahmedabad / Chandigarh(May 04)

PFIZER CHIEF Albert Bourla said on Monday the firm is donating medicines worth $70 million for treatment of Covid patients in India. We are deeply concerned by the critical Covid situation in India and our hearts go out to you your loved ones and all the people of India he said.Read more

Pfizer, Moderna vaccines could be soon in India

The Times Of India - Delhi(May 04)

Meanwhile the government said it has placed orders for 16 crore Covishield and Covaxin vaccines to be supplied in May-July. Adar Poonawalla said SII has govt orders to supply 11 crore more doses over the next few months. PII Read more

Pfizer donates USD 70 mn worth Covid-19 treatment drugs to India

(May 03)

sign in - Pfizer donates USD 70 mn worth Covid-19 treatment drugs to India Global pharma major Pfizer is sending its ... now Pfizer colleagues at distribution centres in the US Europe and Asia are hard at work rushing shipments of Pfizer... Read more

Confident Pfizer shot works against Indian variant: BioNTech co-founder

Hindustan Times - Delhi / Mumbai / Faridabad / Gurgaon / Noida(April 29)

BioNTech co-founder Ugur Sahin on Wednesday voiced confidence that the vaccine that his company jointly developed with Pfizer works against the Indian variant of the coronavirus. Read more

Pfizer offers vaccine to India govt at not-for-profit price

Hindustan Times - Mumbai(April 23)

Rhythma Kaul

People wait in a queue outside a Covid-19 vaccination centre in Goregaon Mumbai on Thursday. Read more

Pfizer: Will supply only through govt channels

The Indian Express - Delhi / Faridabad / Gurgaon / Noida(April 22)

PRABHA RAGHAVAN

PFIZER HAS decided to prioritise orders from the government, and supply doses of its Covid-19 vaccine “only through govern­ment contracts” in India. Read more

Pfizer vaccine is 'extraordinarily effective' against variants: Studies

Business Standard - Mumbai / Delhi / Bangalore / Kolkata / Chandigarh(May 08)

EMILY ANTHES

The studies, which are based on the real-world use of the vac­cine in Qatar and Israel, suggest that the vaccine can prevent the worst outcomes — including severe pneumonia and death — caused by B.l.1.7, the variant first identified in the UK, and B.1.351, the variant first identified in South Africa. Read more

VIEW ALL

Media Contacts

This information is intended for media professionals only. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may ONLY respond to calls and emails from professional journalists.

Email us at: Contactus.India@Pfizer.com
Call us at: +91 - 022 - 6693 2000

If you are not a journalist, please visit Contact Us to reach the appropriate Pfizer contact.

  • COMPANY FACT SHEET
  • LOGOS
  • VALUES
  • CSR
  • COMPANY HISTORY
About UsOur ScienceOur Community EffortsYour Health Career-Seekers News & MediaHealthcare ProfessionalsContact UsTerms And ConditionsPrivacy PolicyAdverse Event ReportingCopyright © 2002- 2022 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of  India and strictly only for informational, educational, academic and/or research purposes and is not intended to substitute for professional medical advice, diagnosis or treatment. While due care and caution has been taken to ensure that the content here is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information here. You may report an adverse event related to Pfizer products by emailing us at IND.AEReporting@pfizer.com or via Fax at: 000800100-5961 / +91-22 3919-771.